Pfizer and Innovent Biologics have signed a cancer drug development partnership worth up to $10.5 billion, covering 12 ...

Pfizer Inc. and China’s Innovent Biologics Inc. signed a global agreement worth as much as $10.5 billion to develop cancer ...

May 29 (Reuters) - China's Innovent Biologics and U.S. pharma giant Pfizer have agreed to a global licensing and ...

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer ...

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Pfizer (PFE) has been a behemoth in pharmaceuticals and drug development for decades, but lately has run into headwinds from vaccine sales, patent expiry, and more. That opens the door for smaller ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a $128 billion market cap. Renowned for its blockbuster drugs like Lipitor ...